Idorsia Ltd
SIX:IDIA
Idorsia Ltd
SIX:IDIA
Price:
2.278 CHF
1.61%
Market Closed
Updated:
Jun 8, 2024
P/E
Price to Earnings
Price to Earnings
-7.7
Current
-3.3
Median
24.4
Industry
Lower
than median
Lower
than industry value
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
P/E
=-7.7
Market Cap
/
429.4m
Net Income
-55.9m
All Countries
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CH |
|
Idorsia Ltd
SIX:IDIA
|
429.4m CHF | -7.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
299.1B USD | 50.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
163.6B USD | 43.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.8B USD | 31 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
110.5B USD | 28.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
139.6B AUD | 37.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.6B USD | 166.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
57.8B USD | -9.7 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 28.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.6T KRW | 100.8 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/E
-2.9
2-Years Forward
P/E
-2.3
3-Years Forward
P/E
-3.3
You don't have any saved screeners yet
